---
title: "Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002422.SZ.md"
symbol: "002422.SZ"
name: "Sichuan Kelun Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-04-17T08:29:57.630Z"
locales:
  - [en](https://longbridge.com/en/quote/002422.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002422.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002422.SZ.md)
---

# Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ)

## Company Overview

Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumor, anti-emetic, antibiotic, VB12, anti-rheumatoid arthritis, multiple sclerosis, anti-schizophrenia, CKD and anti-anemia, polypeptide, and other indications.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.kelun.com](https://www.kelun.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-17T04:30:08.000Z

**Overall: C (0.48)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 68 / 221 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -15.13% |  |
| Net Profit YoY | -42.03% |  |
| P/B Ratio | 2.37 |  |
| Dividend Ratio | 1.74% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 57429860468.46 |  |
| Revenue | 18521879398.70 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 7.29% | B |
| Profit Margin | 9.19% | B |
| Gross Margin | 47.24% | B |
| Revenue YoY | -15.13% | E |
| Net Profit YoY | -42.03% | D |
| Total Assets YoY | 6.75% | B |
| Net Assets YoY | 9.56% | B |
| Cash Flow Margin | 155.24% | B |
| OCF YoY | -15.13% | E |
| Turnover | 0.48 | C |
| Gearing Ratio | 26.46% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Sichuan Kelun Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-15.13%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-42.03%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.37",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.74%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "57429860468.46",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "18521879398.70",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "7.29%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "9.19%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "47.24%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-15.13%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-42.03%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "6.75%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "9.56%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "155.24%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-15.13%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.48",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "26.46%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 33.73 | 78/221 | 31.53 | 28.03 | 23.29 |
| PB | 2.37 | 93/221 | 2.52 | 2.35 | 2.17 |
| PS (TTM) | 3.10 | 70/221 | 3.04 | 2.91 | 2.74 |
| Dividend Yield | 1.74% | 70/221 | 2.18% | 2.02% | 1.87% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | B | B | A |
| 02 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 03 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 04 | Salubris (002294.SZ) | B | C | C | A | B | B |
| 05 | Haisco (002653.SZ) | B | B | B | B | A | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-13T16:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 56% |
| Overweight | 1 | 11% |
| Hold | 2 | 22% |
| Sell | 1 | 11% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 35.23 |
| Highest Target | 45.80 |
| Lowest Target | 29.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002422.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002422.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002422.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002422.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**